Esther Zipperer

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

U. Germing, R. Haas, N. Gattermann, 2009, Haematologica.

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

Luca Malcovati, Mario Cazzola, M. Cazzola, 2011, Haematologica.

Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis

L. Arenillas, M. Cazzola, M. Rozman, 2012, Haematologica.

High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.

U. Germing, R. Kronenwett, N. Gattermann, 2007, Blood.

The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow

G. Mufti, P. Antunović, M. Arno, 2006, Leukemia.

Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome

U. Germing, R. Haas, N. Gattermann, 2013, Annals of Hematology.